FRIDAY, Jan. 26, 2024 -- Childhood bacterial meningitis significantly increases the risk for having at least one of seven long-term disabilities, according to a study published online Jan. 19 in JAMA Network Open.
Salini Mohanty, Dr.P.H., from Merck & Co. Inc. in Rahway, New Jersey, and colleagues assessed the long-term risk for disabilities among individuals diagnosed with bacterial meningitis in childhood. The analysis included 36,230 Swedish individuals diagnosed with bacterial meningitis (younger than 18 years) and matched (1:9) general population controls with up to 35 years of follow-up (1987 through 2021).
"The relative risk of disabilities tended to be highest during the first years after a diagnosis of bacterial meningitis but remained higher during the period starting over five years after diagnosis, suggesting that bacterial meningitis has both acute and long-term consequences," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.